Aastrom Initiates Adult Stem Cell Clinical Trial for Peripheral Arterial Disease - PipelineReview.com | Business Intelligence Center

Aastrom Initiates Adult Stem Cell Clinical Trial for Peripheral Arterial Disease - PipelineReview.com | Business Intelligence Center: "ANN ARBOR, MI, USA | Apr 30, 2007 | Aastrom Biosciences, Inc. (Nasdaq:ASTM), a regenerative medicine company, today announced that it has initiated its U.S. Phase IIb prospective, controlled, randomized, double-blind, multi-center clinical trial to treat patients suffering from peripheral arterial disease (PAD). The Company will use its Tissue Repair Cell (TRC)-based product to treat critical limb ischemia (CLI) in this patient population. Approximately 10 million people in the U.S. suffer from PAD; of this group, 900,000 suffer from the most severe form, CLI, which leads to 100,000 amputations per year."